Hsbc Holdings PLC Makes New $4.97 Million Investment in BioNTech SE Sponsored ADR $BNTX

Hsbc Holdings PLC purchased a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 52,279 shares of the company’s stock, valued at approximately $4,969,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Larson Financial Group LLC boosted its holdings in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. EFG International AG bought a new stake in shares of BioNTech during the 4th quarter worth about $29,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. Finally, Vestcor Inc bought a new stake in BioNTech during the fourth quarter worth approximately $153,000. Institutional investors own 15.52% of the company’s stock.

Insider Activity at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer directly owned 399,387 shares in the company, valued at $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BNTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Monday. Berenberg Bank decreased their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Canaccord Genuity Group lowered their target price on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $117.00 to $135.00 in a research report on Wednesday, May 27th. Finally, Wells Fargo & Company dropped their target price on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $129.12.

BioNTech Trading Down 0.6%

Shares of NASDAQ BNTX opened at $92.98 on Friday. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a 50-day moving average of $92.07 and a two-hundred day moving average of $97.97. The company has a market cap of $23.51 billion, a PE ratio of -15.81 and a beta of 1.32. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The business had revenue of $1.06 billion for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. As a group, equities analysts expect that BioNTech SE Sponsored ADR will post -5.67 earnings per share for the current fiscal year.

BioNTech declared that its Board of Directors has approved a stock buyback program on Thursday, May 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.